Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
11,360 total articles
CNO Financial Group Chief Executive Gary C. Bhojwani disposed of 88,378 shares of company stock on February 17 and 18, 2026, realizing roughly $3.8 million under a Rule 10b5-1 trading plan adopted in August 2025. The transactions, reported on a Form 4 filing, follow the company’s fourth-quarter 2025 report that showed a revenue beat alongside an ea…
CNO Financial Group Inc.'s general counsel, Matthew J. Zimpfer, exercised options to acquire 57,370 shares and sold those same shares across Feb. 17-18, 2026, under a pre-existing Rule 10b5-1 trading plan. The two-day disposition generated about $2.4 million in proceeds, while the company simultaneously disclosed mixed fourth-quarter 2025 financial…
Yvonne K. Franzese, chief human resources officer at CNO Financial Group (CNO), sold a total of 9,000 shares on February 17, 2026, across three separate transactions under a Rule 10b5-1 trading plan adopted August 20, 2025. The sales generated $388,556 in proceeds. The company also reported Q4 2025 results that missed EPS expectations but exceeded …
Abacus Global Management Co-Founder and President Kevin Scott Kirby sold 2,386 shares on February 18, 2026, for $20,001, following a February 13, 2026 vesting-related acquisition of 8,000 shares. The filings show Kirby's direct and indirect holdings, while Abacus announced a new asset-based finance strategy and a planned transfer of its common stoc…
Bradley M. Shuster, executive chairman of NMI Holdings, sold 55,000 common shares on February 18, 2026, for about $2.17 million at a weighted average price of $39.6295. The same filing shows he exercised options to acquire 55,000 shares at $11.10. Post-transaction holdings, valuation metrics and the company’s recent quarterly results are detailed i…
Sean McNealy, Co-Founder and President of Abacus Global Management (ABX), made an indirect purchase of 86,207 common shares on June 4, 2025, at $5.774 per share for $497,759, according to a Form 4/A filing. The shares are held through an LLC jointly owned with his spouse. Since the purchase, ABX shares have risen to $8.88, a 54% increase from McNea…
FormFactor NASDAQ:FORM Chief Executive Officer Mike Slessor sold 8,664 shares of the company's common stock in three transactions on February 18, 2026, under a pre-arranged 10b5-1 trading plan. The sales produced receipts totaling $815596. The company also reported fourth-quarter 2025 results that beat Wall Street expectations for both earnings and…
Exponent Inc. CEO Catherine Corrigan sold 3,920 shares on February 17, 2026, generating about $263,239, and on the same day exercised options for 5,606 shares valued at $151,095. The company reported fourth-quarter 2025 revenue of $147.4 million, an 8% year-over-year increase, and EPS of $0.49, above the $0.4738 estimate. After-hours trading slippe…
MapLight Therapeutics director Robert C. Malenka sold 12,116 shares of voting common stock on February 13, 2026, generating $220,632 in proceeds. The company, valued at roughly $753 million, has pushed forward timelines for two Phase 2 trials and received Fast Track designation for one of its lead candidates, while analysts hold a Strong Buy consen…
Peloton Interactive CEO Peter C. Stern sold 31,461 Class A shares on February 17, 2026, at a weighted average price of $4.1389 to cover tax liabilities tied to the settlement of Restricted Stock Units (RSUs). The sale generated about $130,213. Two days earlier he converted RSUs into 59,714 shares through option exercise. The moves come amid a nearl…
Dion C. Sanders, Peloton Interactive’s Chief Commercial Officer, sold 88,242 shares of Class A common stock on February 17, 2026, for roughly $365,039. Sanders had exercised 235,086 RSUs two days earlier. The insider activity coincides with Peloton’s fiscal 2026 second-quarter results, which came in below analyst estimates on both revenue and earni…
Michael R. McAlevey, HCA Healthcare's Executive Vice President and Chief Legal and Administrative Officer, completed a set of equity transactions in February 2026 that included an open-market sale, exercise and conversion of stock appreciation rights, and a subsequent disposition to satisfy tax obligations. These moves leave him with a reduced dire…
Voss Capital's Voss Value Master Fund reported a purchase of 25,000 Flywire (FLYW) shares on February 13, 2026, for roughly $274,795. The transaction increased the fund's direct stake to 2.3 million shares. The Voss group collectively holds more than 10% of Flywire. Separately, Deutsche Bank and Seaport Global issued positive guidance and price tar…
Sanford J. Hodes, Senior Vice President and Corporate Development Officer at Ryder System, sold 10,527 shares of the company's common stock on February 17, 2026, for $2,212,354 at $210.16 per share after exercising options to acquire 7,610 shares. The company also reported fourth-quarter 2025 earnings of $3.59 per share versus a $3.57 consensus, wh…
Laura H. Bethge, President of Celebrity Cruises at Royal Caribbean Cruises Ltd. (RCL), disposed of 7,854 shares on February 17, 2026, raising $2.56 million. The transaction leaves her with direct ownership of 32,786 shares and indirect ownership of 87 shares through a spouse. The move comes as Royal Caribbean reported Q4 2025 results that met analy…
BridgeBio Pharma Chief Accounting Officer Maricel Apuli reported two recent stock transactions in mid-February 2026, including a sale and a tax-withholding disposition. The company concurrently disclosed positive Phase 3 data for oral infigratinib in achondroplasia and completed a $550 million private offering of convertible senior notes due 2033. …
KKR director Matt Cohler purchased 43,872 shares of KKR & Co. Inc. on February 17, 2026, for a total of $4,514,428 at an average price of $102.90. The transaction increases his direct holdings to 45,477 shares, with an additional 97,568 shares held indirectly in trust. The purchase arrives after KKR reported Q4 2025 adjusted EPS below expectations …
Meta Platforms Chief Financial Officer Susan J. Li completed several equity transactions on February 15, 2026, including the sale of 6,418 Class A shares through a trust for $4,106,043 and the disposition of 11,160 shares withheld for RSU tax obligations valued at $7,139,833. Li also received 23,905 shares via RSU conversion and 13,935 shares via o…
BridgeBio Pharma director Scott Randal W. sold 10,000 shares of common stock on February 17, 2026, generating roughly $754,556 from multiple transactions priced between $74.3421 and $75.9261. The same day he exercised options to acquire 10,000 shares at $16.75 each for $167,500. After these moves he directly owns 11,589 shares and has an indirect h…
Vincent Retort, Executive Vice President for Module Business Unit R&D and Product Development at Lumentum Holdings Inc. (LITE), sold 2,736 shares of company stock on Feb. 17, 2026, for roughly $1.87 million under a previously adopted Rule 10b5-1 plan. The transactions occurred at prices between $530.8035 and $557.8428. The sales follow a Feb. 15 di…
Louisiana-Pacific Corp CEO William Bradley Southern sold 19,232 shares on February 17 and 18, 2026, under a pre-established Rule 10b5-1 plan. The transactions totaled $2,509,317 at prices from $86.87 to $90.12. The disclosure follows the company’s mixed fourth-quarter results, which beat EPS expectations but missed revenue forecasts and triggered a…
PG&E Corp's CEO Patricia K. Poppe sold 31,250 shares on February 18, 2026, for a total of $559,375 under a pre-arranged Rule 10b5-1(c) trading plan. The transaction leaves Poppe with 216,921 shares directly and 1,863,960 shares indirectly through a revocable trust. The disclosure comes as PG&E reported fourth-quarter 2025 earnings per share of $0.3…
Howard F. Hambleton, president of FirstCash Holdings, sold 4,000 shares on February 18, 2026, at $185.12 per share, generating proceeds of $740,480. The transaction was carried out under a 10b5-1 trading plan established on September 11, 2025. After the sale, Hambleton directly holds 35,406 shares. Separately, Canaccord Genuity reiterated its Buy r…
Protagonist Therapeutics director Lewis T. Williams sold 18,000 shares on February 17, 2026, in transactions totaling $1.48 million and exercised options to acquire an equal number of shares at $10.84 each. The activity was disclosed in a Form 4 filing with the Securities and Exchange Commission. Multiple analysts have recently revised price target…
Arvinas Inc.'s chief medical officer, Noah Berkowitz, had 5,685 shares of common stock sold on February 13, 2026, at $11.89 per share to satisfy tax withholding related to vested restricted stock units. The automatic sale generated $67,594 in proceeds and followed a company filing that specifies the transaction was not a discretionary trade. The co…
